Autifony Therapeutics Limited, which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, has announced the start of a Phase Ib biomarker study of the effect of AUT00206, a first-in-class Kv3 ion channel modulator, on patients with schizophrenia.
The clinical trial is being conducted in collaboration with King’s College London, with Professor Oliver Howes as Principal Investigator. It is designed to test the safety, tolerability and pharmacokinetics of AUT00206 in patients with schizophrenia, and also explores the effects of AUT00206 on relevant central biomarkers. The study builds on previous with the Universities of Manchester and Newcastle, who have explored the effects of AUT00206 in preclinical models of brain pathophysiology relevant to schizophrenia.
The study will be conducted with 24 patients who have been diagnosed with schizophrenia within the last five years. A combination of brain imaging, cognition tests, and auditory funciton tests will be used in combination with electrophysiological measures of central nervous function known to be impaired in schizophrenia to assess AUT00206's performance.
Dr Charles Large, CEO of Autifony, commented:
“The commencement of our study of AUT00206 in people suffering from schizophrenia is an important milestone for the company and for our efforts to develop a better treatment for this devastating illness. Our work so far has indicated that AUT00206, which has a completely novel mechanism of action, has the potential to improve the cognitive and negative symptoms of schizophrenia, which current drugs fail to do. AUT00206 may also treat positive symptoms without the typical side effects seen with current medicines. We believe the results of this first study in schizophrenia patients will bring important insights that will help us to plan the next stages of development for this pioneering drug."